PRE-MARKET | October 12, 2016 | $ES_F, $SPY, $DB, $MNK, $IPCI, $LNG, $AAPL, $BABA, $AA

PRE-MARKET MOVERS

1. IPCI, MNK: $IPCI Intellipharmaceutics, Mallinckrodt $MNK Enter Exclusive Licensing Agreement for XR Drug Candidates

2. VOXX:  $VOXX VOXX Int’l Tops Q2 EPS by 13c – Street Insider

3. CUDA:  $CUDA Barracuda Networks Wins Big on the Bottom Line – 247WallSt

4. IDRA:  $IDRA Julian Baker, Idera Pharmaceuticals insider Bought 3.25 million Shares – Thorold News

5. HTGM:  $HTGM HTG Molecular Diagnostics & Merck KGaA Germany, Enter Into a Master Companion Diagnostics Agreement

6. NWL, SWK:  $NWL Stanley Black & Decker to Buy Newell Tools for $1.95 Billion – BBG $SWK

7. CXW:  $CXW SunTrust Robinson Humphrey Upgrades Corrections Corporation of America to Buy, $20 PT

8. MRVL:  $MRVL Credit Suisse Upgrades Marvell to Outperform, $17.50 PT

9. HAWK:  $HAWK Blackhawk Network Stock Gains in After-Hours Trading on Q3 Earnings Beat – TheStreet

10. DB:  $DB Deutsche Bank sells debt to raise cash – Reuters

15. LPLA: $LPLA Nomura Sees Too Many Hurdles to a LPL Investment Deal

16. NSC:  $NSC Avondale Partners Downgrades Norfolk Southern to Underperform

17. SNY:  $SNY Sanofi downwardly revises quarterly sales figure – MarketWatch

18. XLNX:  $XLNX Baird Downgrades Xilinx to Neutral, $52 PT

19. FTNT:  $FTNT Fortinet shares dive after third-quarter outlook slashed – MarketWatch

20. ERIC:  $ERIC Ericsson Shares Plunge on Profit Warning – WSJ

UPGRADES

DOWNGRADES

Trending Social Alerts

1. ERIC:$ERIC Ericsson Shares Plunge on Profit Warning – WSJ

2. IPCI:$IPCI Intellipharmaceutics, Mallinckrodt $MNK Enter Exclusive Licensing Agreement for XR Drug Candidates

3. CUDA:$CUDA Barracuda Networks Wins Big on the Bottom Line – 247WallSt

4. SWK:Stanley Black & Decker $SWK to Acquire Newell Brands’ $NWL Tools Business in $1.95B Deal $$

5. CELG:$CELG and $AGIO Announce Collaborations with Abbott for Diagnostic Identification of IDH Mutati… via @YahooFinance

Trending News Headlines

AstraZeneca has halted a Phase IIa trial of the severe asthma drug it licensed from Synairgen. The Big Pharma took action after an interim analysis raised doubts about whether the study could deliver meaningful data against its primary endpoint, throwing the future of the program into question and wiping 40% off Synairgen’s share price.

Celgene and Agios Form Diagnostic Collaborations for IDH Mutated AML

Mizuho Securities analyst Abhey Lamba previewed Apple’s (NASDAQ: AAPL) Q4 results, reiterating a Buy rating and bumping its price target to $130.00 (from $120.00).Lamba sees revenue and EPS…

Weyerhaeuser Company (NYSE: WY) announced the exploration of strategic alternatives for its timberlands and manufacturing…

Skip to main page content

One bidder for Sears’ Craftsman unit may have just pulled out of the race.

OPEC reported an increase in its oil production in September to a multi-year high and raised its forecast for 2017 non-OPEC supply growth, pointing to a larger surplus in the market next year despite the group’s deal to cut output.

Technology News